NCT05047185View on ClinicalTrials.gov

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Hereditary AngioedemaHereditary Angioedema Type IHereditary Angioedema Type IIHereditary Angioedema Types I and IIHereditary Angioedema AttackHereditary Angioedema With C1 Esterase Inhibitor DeficiencyHereditary Angioedema - Type 1Hereditary Angioedema - Type 2C1 Esterase Inhibitor DeficiencyC1 Inhibitor Deficiency
Interventions
DRUG

Deucrictibant low dose

Deucrictibant softgel capsules for oral use (PHVS416)

DRUG

Deucrictibant high dose

Deucrictibant softgel capsules for oral use (PHVS416)

DRUG

Placebo

Matching placebo capsules for oral use

Trial Locations (19)

1680

Study site, Sofia

10117

Study site, Berlin

20157

Study site, Milan

35128

Study site, Padua

35209

Study site, Birmingham

60323

Study site, Frankfurt

63141

Study site, St Louis

85253

Study site, Paradise Valley

A-1090

Study Site, Vienna

K1H 1E4

Study site, Ottawa

H2W 1R7

Study site, Montreal

D08NHY1

Study site, Dublin

0146

Study site, Palermo

Unknown

Study site, Krakow

BN2 1ES

Study site, Brighton

BS10 5NB

Study site, Bristol

CB2 0QQ

Study site, Cambridge

E1 1FR

Study site, London

SO16 6YD

Study site, Southampton

All Listed Sponsors
lead

Pharvaris Netherlands B.V.

INDUSTRY